NOS3 and metabolic syndrome: These findings have determined O-GlcNAcylation as a novel contributor to the process of hyperglycemia-induced PVAT dysfunction and identified O-GlcNAcylation of eNOS as a possible target for the development of therapies for vascular dysfunction in metabolic syndrome.